Lonza Group AG/Fr. LONN
1D1W1MYTD1Y5YMAX
Capital at risk
About Lonza Group AG
Lonza Group AG is a Swiss multinational chemicals and biotechnology company headquartered in Basel, Switzerland. The company operates primarily in the life sciences sector, offering products and services for pharmaceutical and biotechnology companies, including custom development and manufacturing of active pharmaceutical ingredients, cell and gene therapies, and bioscience solutions. Founded in 1897, Lonza has a significant global presence with numerous production and research facilities worldwide. The company's strategic positioning lies in its comprehensive offering that supports pharmaceutical companies from early-stage development through commercialization, leveraging advanced technologies and extensive expertise in biologics.
- Ticker
- Fr. LONN
- Sector
- Health
- Primary listing
- XSWX
- Employees
- 20,141
- Headquarters
- Basel, Switzerland
- Website
- www.lonza.com
Lonza Group AG Metrics
BasicAdvanced
CHF 39B
-
-CHF 1.57
0.84
CHF 5.00
0.44%
Price and volume
Market cap
CHF 39B
Beta
0.84
52-week high
CHF 597.80
52-week low
CHF 454.60
Average daily volume
113K
Dividend rate
CHF 5.00
Financial strength
Current ratio
1.663
Quick ratio
0.588
Long term debt to equity
41.622
Total debt to equity
51.116
Interest coverage (TTM)
10.22%
Profitability
EBITDA (TTM)
2,390
Gross margin (TTM)
37.14%
Net profit margin (TTM)
-1.60%
Operating margin (TTM)
23.49%
Effective tax rate (TTM)
17.80%
Revenue per employee (TTM)
CHF 340,000
Management effectiveness
Return on assets (TTM)
5.44%
Return on equity (TTM)
12.90%
Valuation
Price to revenue (TTM)
5.722
Price to book
4.82
Price to tangible book (TTM)
6.7
Price to free cash flow (TTM)
262.086
Free cash flow yield (TTM)
0.38%
Free cash flow per share (TTM)
2.147
Dividend yield (TTM)
0.89%
Forward dividend yield
0.44%
Growth
Revenue change (TTM)
25.91%
Earnings per share change (TTM)
-115.18%
3-year revenue growth (CAGR)
2.83%
10-year revenue growth (CAGR)
5.78%
3-year earnings per share growth (CAGR)
-53.12%
10-year earnings per share growth (CAGR)
-13.64%
3-year dividend per share growth (CAGR)
12.62%
10-year dividend per share growth (CAGR)
7.18%
Bulls say / Bears say
Lonza raised its full-year core EBITDA margin guidance to 33–34% (from over 32%), reflecting strong operational execution and contributions from maturing growth projects. (Reuters)
Management maintained full-year sales growth guidance at 11–12% CER, signalling confidence in sustained top-line momentum despite phasing effects. (Reuters)
RBC analyst Charles Weston noted that the strong first-half performance and clear phasing communication had been broadly anticipated, reinforcing management transparency and investor trust. (Reuters)
Lonza reiterated that growth and profitability would moderate in the second half of 2026, suggesting a deceleration of momentum in H2. (Reuters)
The share price fell about 4% following the guidance update, indicating investor disappointment and potential downside risk. (Reuters)
Maintaining the full-year sales target at 11–12% CER, despite strong H1 growth, highlights limited upside for additional top-line expansion in H2. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 22 Aug 2026.
Upcoming events
No upcoming events
Funds containing Lonza Group AG
AllEURGBPUSD
Fund name | Fund size | Fr. LONN weighting |
|---|---|---|
iShares STOXX Europe 600 Health Care€EXV4 | €704M | 2.55% |
iShares MSCI Europe Health Care Sector€ESIH | €863M | 2.54% |
iShares MSCI Europe Health Care Sector£ESIH | £742M | 2.54% |
iShares MSCI Europe SRI€IESE | €3.1B | 1.87% |
iShares MSCI Europe SRI£IESG | £2.6B | 1.82% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.